AxoGen, Inc. (AXGN) Earnings

Management highlights

- Commercial Execution and Growth: Active surgeon count increased meaningfully in Q2, with more than 210 new active surgeons added year-to-date (over 135 in high potential accounts), exceeding the 2026 full-year plan. The breast segment now has ~215 active programs (up 40 year-over-year) and ~560 active surgeons (up 150 year-over-year), with accelerating growth driven by improved coverage, increased awareness, and expanded salesforce capacity. The commercial footprint now totals 172 sales and market development staff, with 15 added year-to-date (9 in extremities, 6 in breast), bringing the extremities team to 140 and breast team to 29. Return on sales expansion investments has exceeded expectations, with new hires contributing meaningfully to growth early in their tenures. High potential accounts delivered 20% year-over-year productivity growth, reaching 690 active accounts (up 11 year-to-date), while non-high potential accounts delivered 24% year-over-year productivity per account growth. Nine professional education programs were held year-to-date, training 155 surgeons. - Reimbursement and Coverage: Commercial payer coverage for Avance currently reaches ~86% of U.S. covered lives. Aetna, the largest remaining non-covering payer, continues its policy review originally expected to conclude in June. A favorable Aetna decision would bring total coverage to ~95% of U.S. commercial covered lives, leaving only Humana and a small number of regional payers without coverage. - Clinical Evidence Development: The prospective randomized REPOSE study for Axigard nerve cap was published, showing positive outcomes for pain burden, medication reliance, and post-neurectomy recovery, strengthening the evidence base for the company's nerve protection portfolio. The first U.S. site was activated for the Nerve Restore study, which compares Avance to the gold standard sural nerve autograft for complex peripheral nerve reconstructions, with additional site activations planned for H2 2026. The Embrace study for nipple-sparing mastectomy and breast reconstruction remains on track for initiation in late 2026. - Innovation and Business Development: A minority strategic investment was made in Trace Biosciences, including a limited right of first refusal. Trace's NerveTrace real-time nerve imaging technology is complementary to Axygen's nerve repair portfolio, helping surgeons identify and protect nerves intraoperatively; the technology is expected to broadly benefit all of Axygen's indication areas. Trace has FDA clearance for its IND and is advancing through Phase II/III trials toward NDA submission. The prostate nerve reconstruction program remains on track, with over 100 patients across more than 10 sites, half of whom have over six months of follow-up data; a full strategy update will be provided in Q3/Q4 2026.

Guidance

- Full year 2026 revenue guidance was upwardly revised to at least 24% year-over-year growth, corresponding to total revenue of at least $279 million, reflecting better-than-expected breast growth and salesforce productivity gains. - Full year 2026 gross margin guidance was downwardly revised to at least 73%, due to faster-than-expected growth in higher-cost long-length Avance grafts driven by the accelerating breast business; the pricing and production efficiency initiatives planned to offset margin pressure will not impact full-year 2026 results. Gross margin is expected to be higher in Q3 2026 than in Q4 2026, with long-term gross margin targeted at 75%. - Axygen reaffirms it will be free cash flow positive for full year 2026. The guidance does not assume any material benefit from future Aetna or other new payer coverage decisions. - An updated long-term financial framework will be released in Q1 2027, to allow sufficient time to assess the full impact of recent coverage wins and product approvals. Axygen has consistently outperformed its long-range target of 15-20% revenue CAGR and expects to continue outperforming this range.

Segment performance

Total Q2 2026 revenue was $69.7 million, representing 23.1% year-over-year growth. Avance, the company's core product, contributed 65% of total Q2 revenue and 63% of year-to-date revenue, up from ~60% in 2025. The breast segment grew over 50% year-over-year in Q2, driving approximately two-thirds of the quarter's total growth, and reached 47% year-over-year year-to-date growth; breast now accounts for more than 50% of total revenue, pushing extremities below 50% of total sales for the first time. The combined extremities, OMF and head and neck, and other indications segment delivered 15% year-over-year year-to-date growth. High potential accounts represent 60% of total year-to-date revenue and 51% of year-to-date growth, while non-high potential accounts represent 40% of total year-to-date revenue.

Risks & headwinds

- Faster-than-expected breast growth has shifted product mix to higher-cost long-length Avance grafts more than forecast, creating unanticipated gross margin pressure in 2026 that cannot be fully offset this year. - Payer coverage expansion takes 6+ months from approval to fully impact revenue, as coverage must be socialized to providers and institutions, and payment rates must be negotiated, leading to delayed realization of coverage benefits. - The clinical evidence for new indications (including prostate nerve reconstruction and Trace's imaging technology) is still early-stage, and positive early trends may not hold as more follow-up data is collected. - Expansion of the commercial sales footprint is constrained by the requirement to maintain profitability, limiting the pace of geographic and market expansion.

Analyst Q&A

• Q: Given the deceleration in overall sequential growth and accelerating breast growth, how are non-breast markets performing in Q2, what are the core assumptions for H2 2026 growth, and what is the outlook for Aetna coverage timing? /

  A: Non-breast core markets (extremities, OMF and head and neck) are growing handsomely in line with prior guidance, even as their relative contribution to total growth has declined with breast's acceleration. The core drivers of H2 growth are expanding sales footprint (which has delivered strong returns on prior investments) and growing patient and surgeon awareness, particularly in the breast market; the company will continue aggressive sales expansion without sacrificing profitability. Aetna's review is taking longer than the historical June timeline expected, but the delay indicates Aetna is conducting a thorough review rather than rubber-stamping the policy, and the company remains optimistic about a favorable outcome.

• Q: Why is breast growth pressuring gross margin, despite higher expected ASPs, and when will pricing and production initiatives offset this pressure? /

  A: Gross margin pressure stems from faster-than-forecast breast growth shifting the overall product mix to higher-cost long-length Avance grafts, which the original 2026 gross margin plan did not account for. Pricing for longer grafts does not currently scale linearly with production costs, a gap management will address via pricing adjustments and manufacturing efficiency initiatives. These changes will not impact the remaining 2026 revenue due to implementation timelines, but long-term gross margin for the overall business is still targeted at 75%.

• Q: Why did Axygen choose to make a minority investment in Trace Biosciences now, and what indication will it benefit most? /

  A: Axygen has long evaluated nerve imaging technologies, as the ability to clearly visualize nerves in complex wound beds is a major unmet need in nerve care, a core part of the company's long-term innovation strategy. The opportunity became available at this time, and the minority stake structure preserves capital discipline while giving Axygen exposure to a highly complementary technology that pairs with its existing nerve repair portfolio. NerveTrace will benefit all of Axygen's indication areas, from messy trauma wound beds in extremities to elective breast procedures, by making nerve identification easier and more accurate for surgeons.

• Q: What is the current penetration of the breast market, how much growth runway remains, and what are the key bottlenecks? /

  A: Axygen is still very early in breast market development; the total addressable market of breast procedure sites is approximately 1,200, and the company currently has only 215 active programs, leaving substantial growth runway. Most patients and many surgeons remain unaware of nerve restoration options for breast reconstruction, so ongoing market development and education will drive high growth for years to come.